deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05385978

A Study of Distal Jejunal-release Dextrose in Obese Participants

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects

Sponsor: Aphaia Pharma US LLC

Conditions Obese
Interventions APHD-012 APHD-012P
Updated 5 times since 2022 Last updated: Oct 14, 2024 Started: Nov 1, 2022 Primary completion: Nov 11, 2024 Completion: Nov 11, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Obese and is currently ongoing. Aphaia Pharma US LLC leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshotNot Yet Recruiting~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshotActive Not Recruiting

Change History

5 versions recorded

  1. Nov 2024 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Feb 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Jun 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aphaia Pharma US LLC
Data source: Aphaia Pharma US LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations